Our thinking

Navigating change: US M&A H1 2018

What's inside

Clouds are forming on the horizon, however appetites for big-ticket deals have not yet diminished

US M&A defies market uncertainty

An impressive first half of the year for US dealmaking reflects M&A's enduring value in an uncertain market

After a very strong 2017—when M&A in the US reached its third-highest overall deal value since the financial crisis—deal value grew again in the first half of 2018. Compared to H1 2017, value rose 30.5 percent to US$794.8 billion when compared to the same period in 2017, while deal volumes held steady.

Activity has been brisk despite increasing macro-economic headwinds. The Federal Reserve recently raised interest rates and signaled its intention to do so again twice more before the year is out. Threats of a bourgeoning global trade war are intensifying after the imposition of tariffs by the US and other large economies. And the US stock market has experienced significantly higher volatility this year than it did last.

One could reasonably expect that M&A would cool against this backdrop, but the fact that it has not suggests that deals are going ahead for essential strategic reasons rather than opportunistic ones.

Technology and its disruptive impact across all sectors is one of the main factors that has made M&A a necessity. The impact has been most apparent in sectors such as retail and healthcare, where digital platforms are ideally placed to disrupt established service and distribution channels. No sector has been untouched, however. Unless non-tech companies have the resources in-house to write their own software and algorithms—and most do not—M&A may be the best option to keep pace with dynamic change.

We expect the second half of the year to be busy, but no one can afford to ignore the threats posed by rising interest rates, increasing protectionism, an incipient trade war that could increase tariffs, a potentially inverting yield curve, unsustainable pricing demands and a volatile stock market. Companies will need to navigate these dynamics if M&A's bull run is to continue.

 

John Reiss
Global Head of M&A
White & Case

Gregory Pryor
Head of Americas M&A
White & Case

 

Navigating change: H1 in review

First-half activity remains on par with 2016, as strong fundamentals continue to drive M&A

New York City buildings

PE hits new post-crisis high

Despite intensifying competition within the market, US private equity activity is yet to show signs of a downturn

aerial photography of Empire State Building in New York

Sector watch

Energy, mining & utilities leads the field

Bulky oil & gas deals pushed energy, mining & utilities close to the top spot in H1, while digital disruption ensured a steady flow of tech deals

large metal pipes

Technology M&A gets white hot in 2018

Dealmakers across all industries are looking to secure US tech assets in order to keep up with the technological changes disrupting their industries

urban area at night

Consumer firms adapt to survive

Despite a drop in headline figures, M&A within the US consumer sector remains an important method to secure long-term growth

root vegetables

Oil & gas M&A gains cautious ground

A steadying oil price signals a brighter future for oil & gas M&A, yet market caution remains

oil pipelines

Big-ticket deals drive pharma M&A

Activity in the sector is fueled by the need to refill product pipelines and navigate convergence between health and tech firms

medicines

Industrials & chemicals M&A gathers pace

Corporate repositioning and tax reform are two key trends driving M&A in the sector

welding

Is blockchain M&A poised to accelerate?

US dealmakers are learning to navigate the complex world of blockchain M&A, but they will have to proceed with care in heavily regulated sectors

building windows

In focus: Financial services regulation

An overview of the financial regulatory landscape and key trends to watch

US dollar

Decision time for M&A in Delaware

Noteworthy rulings out of the Delaware Supreme Court and the Court of Chancery in the past six months are already having consequences for M&A activity

pedestrian streets

Spotlight on public companies: Cybersecurity and governance

The number and severity of cybersecurity incidents at major companies has increased, causing regulators to take a tougher approach. We look at five practical steps companies can take to manage these risks

computer programming

Conclusion

Key trends to watch in the months ahead

Acquirers shrugged off macro-economic uncertainty in the first half of the year to secure deals of strategic necessity

New York City buildings

Meet our partners

Global M&A leaders

John Reiss

 

John Reiss
Partner, New York

 

Gregory Pryor

 

Gregory Pryor
Partner, New York

 

 Dr. Jörg Kraffel

Dr. Jörg Kraffel
Partner, Berlin

 

Christopher Kelly

 

Christopher Kelly
Partner, Hong Kong

 

Allan Taylor

 

Allan Taylor
Partner, London

 

 Barrye Wall

 

Barrye Wall
Partner, Singapore

 

John Cunningham

John Cunningham
Partner, London

 

Alexandre Ippolito

Alexandre Ippolito
Partner, Paris

 

Big-ticket deals drive pharma M&A

Activity in the sector is fueled by the need to refill product pipelines and navigate convergence between health and tech firms

Insight
|
4 min read

The pharma, medical and biotech sector delivered 247 deals worth US$65.4 billion in the first half of 2018, with deal value down by 31 percent year-on-year.

 

Top pharma & healthcare deals
H1 2018

1: Sanofi SA bought Bioverativ Inc. for US$11.1 billion

2: Kohlberg Kravis Roberts & Co. agreed to buy Envision Healthcare Corporation for US$9.4 billion

3: Celgene Corporation bought a 90.37% stake in Juno Therapeutics Inc. for US$8.2 billion

    
     

Big pharma, big deals

Despite the downturn in overall deal value, the sector continues to deliver large, industry-shifting transactions, such as Sanofi's US$11.1 billion acquisition of Bioverativ—its largest deal in seven years—and KKR's US$9.4 billion announced acquisition of Envision Healthcare. These were two of the largest transactions in the sector in the US in the first half of 2018.

 

US$65.4 billion

The value of 247 deals targeting the US pharma sector in H1 2018

Building pipelines, expanding horizons

As in previous years, M&A in the sector has been driven by the need for large pharma groups to refill their product pipelines as blockbuster drugs go off patent and move into new treatment areas.

Sanofi's purchase of Bioverativ, a maker of hemophilia medicines, for example, boosts the French drug company's position in the treatment of rare diseases. Celgene's US$8.2 billion acquisition of a 90 percent stake in Juno Therapeutics, a developer of blood cancer drugs, which is close to having a treatment for lymphoma cleared by regulators in 2019, was underpinned by a similar rationale. Celgene's best-selling medicine Revlimid loses patent protection in 2022, making the Juno acquisition a key strategic investment for the group. In the case of the Novartis purchase of AveXis, a gene therapy treatment developer, the deal moves Novartis into a new and fast-growing area.

 

31%

Percentage decrease in deal value compared to H1 2017

Connected health

As in other sectors, pharma M&A has been influenced by the trend toward convergence with the technology sector. Swiss pharmaceuticals group Roche, for example, paid US$1.9 billion for a stake in health-tech company Flatiron Health, with a view to speeding up research by using Flatiron's software and data analytics.

Large pharma companies are cash-rich and enjoy strong credit ratings. They will continue acquiring smaller biotech companies in order to renew pipelines and keep pace with the development of new treatments. As a consequence, M&A in the sector is expected to accelerate into the second half of the year.

 

 

This publication is provided for your convenience and does not constitute legal advice. This publication is protected by copyright.
© 2018 White & Case LLP

 

Top